Compare Stocks: TAOX, IMUX, VANI, and CPIX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPIX Cumberland Pharmaceuticals	$7.49 +4.5%	$7.41	$1.85 ▼ $9.28	$112.20M	0.06	390,520 shs	58,559 shs
IMUX Immunic	$6.66 -3.3%	$12.33	$5.06 ▼ $17.43	$90.84M	1.45	300,193 shs	438,037 shs
TAOX Synaptogenix	$3.50 -4.9%	$3.94	$3.07 ▼ $10.00	$27.48M	1.73	158,987 shs	96,866 shs
VANI Vivani Medical	$1.16 -1.7%	$1.32	$0.92 ▼ $1.92	$104.63M	2.35	330,862 shs	134,911 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPIX Cumberland Pharmaceuticals	+2.43%	+0.42%	+12.21%	-8.08%	+113.39%
IMUX Immunic	-13.33%	-11.89%	-39.67%	-54.37%	-22.98%
TAOX Synaptogenix	-2.13%	-19.30%	-5.64%	-3.92%	-61.43%
VANI Vivani Medical	-0.84%	-4.84%	-7.09%	-16.31%	-12.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPIX Cumberland Pharmaceuticals	$7.49 +4.5%	$7.41	$1.85 ▼ $9.28	$112.20M	0.06	390,520 shs	58,559 shs
IMUX Immunic	$6.66 -3.3%	$12.33	$5.06 ▼ $17.43	$90.84M	1.45	300,193 shs	438,037 shs
TAOX Synaptogenix	$3.50 -4.9%	$3.94	$3.07 ▼ $10.00	$27.48M	1.73	158,987 shs	96,866 shs
VANI Vivani Medical	$1.16 -1.7%	$1.32	$0.92 ▼ $1.92	$104.63M	2.35	330,862 shs	134,911 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPIX Cumberland Pharmaceuticals	+2.43%	+0.42%	+12.21%	-8.08%	+113.39%
IMUX Immunic	-13.33%	-11.89%	-39.67%	-54.37%	-22.98%
TAOX Synaptogenix	-2.13%	-19.30%	-5.64%	-3.92%	-61.43%
VANI Vivani Medical	-0.84%	-4.84%	-7.09%	-16.31%	-12.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPIX Cumberland Pharmaceuticals	1.00	Sell	N/A	N/A
IMUX Immunic	3.00	Buy	$35.43	434.29% Upside
TAOX Synaptogenix	1.00	Sell	N/A	N/A
VANI Vivani Medical	2.25	Hold	$3.75	219.15% Upside

Current Analyst Ratings Breakdown

Latest TAOX, IMUX, VANI, and CPIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/21/2026	CPIX Cumberland Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/10/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$45.00
9/10/2026	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$22.00
9/1/2026	IMUX Immunic	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/26/2026	IMUX Immunic	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/17/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$45.00
7/29/2026	IMUX Immunic	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
7/17/2026	TAOX Synaptogenix	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPIX Cumberland Pharmaceuticals	$44.52M	2.47	$0.38 per share	19.09	$1.64 per share	4.47
IMUX Immunic	N/A	N/A	N/A	N/A	($0.55) per share	N/A
TAOX Synaptogenix	$300K	91.71	N/A	N/A	$2.83 per share	1.24
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPIX Cumberland Pharmaceuticals	-$2.84M	-$0.71	N/A	N/A	N/A	-34.40%	-28.81%	-9.25%	11/3/2026 (Estimated)
IMUX Immunic	-$97.17M	-$4.38	N/A	N/A	N/A	N/A	-157.89%	-107.88%	11/12/2026 (Estimated)
TAOX Synaptogenix	-$28.74M	-$3.85	N/A	N/A	N/A	-2,153.97%	-128.51%	-97.54%	N/A
VANI Vivani Medical	-$26.61M	-$0.35	N/A	N/A	N/A	N/A	-191.05%	-70.91%	11/12/2026 (Estimated)

Latest TAOX, IMUX, VANI, and CPIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	CPIX Cumberland Pharmaceuticals	-$0.13	N/A	N/A	N/A	$8.50 million	N/A
8/13/2026	Q2 2026	TAOX Synaptogenix	N/A	-$1.83	N/A	-$1.83	N/A	$0.09 million
8/13/2026	Q2 2026	VANI Vivani Medical	-$0.0833	-$0.07	+$0.0133	-$0.07	N/A	N/A
8/11/2026	Q2 2026	IMUX Immunic	-$1.16	-$0.80	+$0.36	-$0.80	N/A	N/A
8/4/2026	Q2 2026	CPIX Cumberland Pharmaceuticals	-$0.13	-$0.20	-$0.07	-$0.29	$8.50 million	$0.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPIX Cumberland Pharmaceuticals	N/A	0.96	0.96
IMUX Immunic	N/A	5.05	5.05
TAOX Synaptogenix	N/A	19.98	19.98
VANI Vivani Medical	N/A	3.25	3.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPIX Cumberland Pharmaceuticals	15.51%
IMUX Immunic	51.82%
TAOX Synaptogenix	10.34%
VANI Vivani Medical	6.78%

Insider Ownership

Company	Insider Ownership
CPIX Cumberland Pharmaceuticals	42.07%
IMUX Immunic	5.49%
TAOX Synaptogenix	2.70%
VANI Vivani Medical	53.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPIX Cumberland Pharmaceuticals	93	14.98 million	8.68 million	Optionable
IMUX Immunic	95	13.64 million	12.90 million	Optionable
TAOX Synaptogenix	4	7.85 million	7.28 million	N/A
VANI Vivani Medical	36	90.20 million	42.13 million	Optionable

TAOX, IMUX, VANI, and CPIX Headlines

Recent News About These Companies

Vivani Medical Announces Participation in Upcoming October 2026 Investor Conferences

October 12 at 10:54 AM | biospace.comB

Vivani Medical to Participate in Maxim Growth Summit and ThinkEquity Conference in New York

October 12 at 7:31 AM | quiverquant.comQ

Vivani Medical Announces Merger Deal Involving Cortigent

September 16, 2026 | tipranks.com

Vivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor Conferences

September 3, 2026 | quiverquant.comQ

Vivani Medical Announces Participation in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Vivani Medical (VANI) and InspireMD (NSPR)

August 20, 2026 | theglobeandmail.com

Vivani Medical Inc U5P

August 19, 2026 | morningstar.comM

Vivani Medical Updates Investors with Regulation FD Presentation

August 17, 2026 | tipranks.com

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | finance.yahoo.com

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | globenewswire.com

Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial

August 6, 2026 | finance.yahoo.com

ClearOne (CLRO) stock soars over 98% after hours: Here's what you need to know

August 6, 2026 | msn.com

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic ...

August 6, 2026 | finance.yahoo.com

Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial

August 6, 2026 | tipranks.com

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

July 14, 2026 | globenewswire.com

Next Frontier In Weight Loss? New Implant Looks To Lock In GLP-1 Results

July 14, 2026 | msn.com

The next GLP-1 bet? Implant draws Novo interest

July 13, 2026 | beckershospitalreview.comB

Vivani Medical

July 13, 2026 | fool.com

Weight-loss implant could one day replace Ozempic injections

July 12, 2026 | msn.com

Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal

July 9, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TAOX, IMUX, VANI, and CPIX Company Descriptions

Cumberland Pharmaceuticals NASDAQ:CPIX

$7.49 +0.32 (+4.46%)

Closing price 04:00 PM Eastern

Extended Trading

$7.58 +0.09 (+1.13%)

As of 04:10 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Immunic NASDAQ:IMUX

$6.66 -0.23 (-3.34%)

Closing price 04:00 PM Eastern

Extended Trading

$6.53 -0.13 (-1.95%)

As of 05:25 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Synaptogenix NASDAQ:TAOX

$3.50 -0.18 (-4.89%)

Closing price 04:00 PM Eastern

Extended Trading

$3.58 +0.08 (+2.34%)

As of 05:07 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Vivani Medical NASDAQ:VANI

$1.16 -0.02 (-1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 +0.02 (+2.07%)

As of 04:50 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TAOX, IMUX, VANI, and CPIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TAOX, IMUX, VANI, and CPIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TAOX, IMUX, VANI, and CPIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TAOX, IMUX, VANI, and CPIX Company Descriptions

Cumberland Pharmaceuticals NASDAQ:CPIX

Immunic NASDAQ:IMUX

Synaptogenix NASDAQ:TAOX

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TAOX, IMUX, VANI, and CPIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TAOX, IMUX, VANI, and CPIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TAOX, IMUX, VANI, and CPIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TAOX, IMUX, VANI, and CPIX Company Descriptions

Cumberland Pharmaceuticals NASDAQ:CPIX

Immunic NASDAQ:IMUX

Synaptogenix NASDAQ:TAOX

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools